QuartzBio may now include SolveBio's genomic and clinical data analytics technologies into its own multiomics data integration platform thanks to the acquisition. This will improve QuartzBio's capabilities for the discovery of biomarkers in therapeutic domains like oncology, autoimmune disease, and CNS sickness.
"QuartzBio's acquisition of SolveBio is a major step forward in our goal to solve biomarker data management for the pharmaceutical and biotech industry," SolveBio Cofounder and Chief Technology Officer David Caplan said in a statement. "By joining QuartzBio's … team, we will be able to provide the comprehensive solution our clients need to get precision treatments out to patients faster."
Precision for Medicine, the parent firm of QuartzBio, is a division of Precision Medicine Group with offices in Frederick, Maryland. SimplicityBio, a developer of artificial intelligence technology, was previously bought by the company, and its technology was merged.